NCT00380133View on ClinicalTrials.gov

Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

SB681323

5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles

DRUG

Prednisolone

5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)

DRUG

Placebo

Tablets matched to SB681323 or prednisolone

Trial Locations (1)

M23 9LT

GSK Investigational Site, Manchester

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY